A new trading day began on Monday, with Ovid Therapeutics Inc (NASDAQ: OVID) stock price up 6.50% from the previous day of trading, before settling in for the closing price of $0.27. OVID’s price has ranged from $0.24 to $3.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -67.57%. With a float of $59.51 million, this company’s outstanding shares have now reached $71.11 million.
Let’s look at the performance matrix of the company that is accounted for 23 employees. In terms of profitability, gross margin is 72.99%, operating margin of -10404.2%, and the pretax margin is -4557.12%.
Ovid Therapeutics Inc (OVID) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ovid Therapeutics Inc is 16.32%, while institutional ownership is 54.79%. The most recent insider transaction that took place on Feb 26 ’25, was worth 2,956. In this transaction President and COO of this company sold 5,279 shares at a rate of $0.56, taking the stock ownership to the 73,406 shares. Before that another transaction happened on Feb 26 ’25, when Company’s CBFO sold 3,902 for $0.56, making the entire transaction worth $2,185. This insider now owns 67,973 shares in total.
Ovid Therapeutics Inc (OVID) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -67.57% per share during the next fiscal year.
Ovid Therapeutics Inc (NASDAQ: OVID) Trading Performance Indicators
Here are Ovid Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 37.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.66 in one year’s time.
Technical Analysis of Ovid Therapeutics Inc (OVID)
Ovid Therapeutics Inc (NASDAQ: OVID) saw its 5-day average volume 0.71 million, a positive change from its year-to-date volume of 0.42 million. As of the previous 9 days, the stock’s Stochastic %D was 39.76%. Additionally, its Average True Range was 0.03.
During the past 100 days, Ovid Therapeutics Inc’s (OVID) raw stochastic average was set at 6.18%, which indicates a significant decrease from 33.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.80% in the past 14 days, which was lower than the 82.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3113, while its 200-day Moving Average is $0.7956.
